<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122316</url>
  </required_header>
  <id_info>
    <org_study_id>09-06-086-02</org_study_id>
    <nct_id>NCT01122316</nct_id>
  </id_info>
  <brief_title>Management of Diabetes With Metformin In Patients With Chronic Heart Failure</brief_title>
  <official_title>Management of Diabetes With Metformin In Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ahmanson-UCLA Cardiomyopathy Center is conducting a clinical research study that will&#xD;
      assess the use of the medication metformin to improve quality of life, exercise capacity, and&#xD;
      improved outcomes with patients that have both heart failure and diabetes.&#xD;
&#xD;
      If you participate in this study, you will receive the drug metformin for approximately 3&#xD;
      months. During the study you will undergo comprehensive testing which includes blood draws,&#xD;
      an echocardiogram, and an magnetic resonance imaging (MRI)(if you do not have a pacemaker or&#xD;
      defibrillator). You will also fill out a questionnaire and keep a blood glucose log.&#xD;
&#xD;
      You must be 18 years old to participate. The study drugs, study follow-up visits, and&#xD;
      laboratory tests will be provided free of charge. Participants will be reimbursed up to $200&#xD;
      for their time and travel expenses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) affects 5 million individuals in the United States including over 10% of&#xD;
      elderly persons &gt;75 years. HF mortality is high, with approximately 20% 1-year risk of death&#xD;
      (1). Diabetes (DM) is a common co-morbidity in patients with HF, present in approximately 25%&#xD;
      of stable outpatients and 40% of hospitalized patients with HF (2). Diabetes in HF patients&#xD;
      is associated with higher mortality (3,4). Hyperglycemia is independently associated with&#xD;
      hospitalization for HF, longer length of stay during HF hospitalization, as well as higher&#xD;
      in-hospital HF mortality (5-7). Furthermore, HF patients with more symptoms and worse&#xD;
      functional status are more likely to have insulin resistance (8,9).&#xD;
&#xD;
      Despite the abundance of evidence linking diabetes, insulin resistance, and hyperglycemia to&#xD;
      impaired functional status and worse outcomes in patients with HF, there is lack of data and&#xD;
      guidelines on optimal strategies to manage diabetes in patients with chronic HF. In&#xD;
      retrospective studies, many diabetes medications in HF have been associated with harm&#xD;
      including insulin, thiazolidinediones, and sulfonylureas (10). The only anti-hyperglycemic&#xD;
      medication that has been associated in retrospective studies with benefit in patients with HF&#xD;
      and diabetes is metformin, which recently had its &quot;black box warning&quot; in HF lifted by the&#xD;
      FDA, although most physicians are unaware of the change in labeling (10-12). Our analysis of&#xD;
      data on 401 advanced, systolic HF patients with DM followed at the Ahmanson-UCLA&#xD;
      Cardiomyopathy Center also found metformin therapy to be associated with improvement of left&#xD;
      ventricular ejection fraction (LVEF) as well as decreased 1-year mortality (figure 1)(13).&#xD;
&#xD;
      Glycemic control in HF patients has not been prospectively studied; however, improved&#xD;
      glycemic control has potential benefits in HF, including improvement of myocardial glucose&#xD;
      utilization, decrease of potentially cardiotoxic free fatty acids, and reduced accumulation&#xD;
      of myocardial collagen and advanced glycation end-products (14,15). Metformin therapy,&#xD;
      compared to insulin and other antidiabetic medications, has potentially beneficial mechanisms&#xD;
      of action in HF including insulin sensitization, improvement in lipid profiles, and more&#xD;
      efficient myocardial metabolism (16,17). The purpose of this study is to gather pilot data&#xD;
      for an anticipated comprehensive study DM management in HF, with the goal of NIH funding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health-Related Quality of Life (HRQoL)</measure>
    <time_frame>3 months</time_frame>
    <description>HRQoL as assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ)&#xD;
The MLHFQ is a self-administered questionnaire for patients with HF, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score range 0-105. Lower scores indicate better health-related quality of life (HRQoL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycated Hemoglobin (HbA1c)</measure>
    <time_frame>3 months</time_frame>
    <description>The HbA1c test measures how much glucose is bound to hemoglobin in the red blood cells. The test shows the average level of glucose in blood for the past 3 months (the average lifespan of red blood cells). If glucose levels have been high over recent weeks, the hemoglobin A1c test will be higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>3 months</time_frame>
    <description>Obtained from Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Level as a Measure of Renal Function</measure>
    <time_frame>3 months</time_frame>
    <description>Serum creatinine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Systolic HF of any etiology (left ventricular ejection fraction ≤ 40%)&#xD;
&#xD;
          -  Previously-diagnosed, inadequately controlled DM (HbA1c≥7.5%)&#xD;
&#xD;
          -  On any combination of anti-diabetic medications excluding metformin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current metformin therapy&#xD;
&#xD;
          -  Previous intolerance to metformin therapy&#xD;
&#xD;
          -  Renal dysfunction (creatinine clearance &lt; 60 ml/minute)&#xD;
&#xD;
          -  History of lactic acidosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamara Horwich, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmanson-UCLA Cardiomyopathy Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7368</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <results_first_submitted>August 20, 2020</results_first_submitted>
  <results_first_submitted_qc>August 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Tamara Horwich</investigator_full_name>
    <investigator_title>Tamara Horwich, MD, MS</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Health-Related Quality of Life (HRQoL)</title>
        <description>HRQoL as assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ)&#xD;
The MLHFQ is a self-administered questionnaire for patients with HF, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score range 0-105. Lower scores indicate better health-related quality of life (HRQoL).</description>
        <time_frame>3 months</time_frame>
        <population>Analysis includes participants who completed intervention and final study assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-Related Quality of Life (HRQoL)</title>
          <description>HRQoL as assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ)&#xD;
The MLHFQ is a self-administered questionnaire for patients with HF, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score range 0-105. Lower scores indicate better health-related quality of life (HRQoL).</description>
          <population>Analysis includes participants who completed intervention and final study assessment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycated Hemoglobin (HbA1c)</title>
        <description>The HbA1c test measures how much glucose is bound to hemoglobin in the red blood cells. The test shows the average level of glucose in blood for the past 3 months (the average lifespan of red blood cells). If glucose levels have been high over recent weeks, the hemoglobin A1c test will be higher.</description>
        <time_frame>3 months</time_frame>
        <population>Analysis includes participants who completed intervention and final study assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycated Hemoglobin (HbA1c)</title>
          <description>The HbA1c test measures how much glucose is bound to hemoglobin in the red blood cells. The test shows the average level of glucose in blood for the past 3 months (the average lifespan of red blood cells). If glucose levels have been high over recent weeks, the hemoglobin A1c test will be higher.</description>
          <population>Analysis includes participants who completed intervention and final study assessment</population>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <description>Obtained from Echocardiography</description>
        <time_frame>3 months</time_frame>
        <population>Analysis includes participants who completed intervention and final study assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <description>Obtained from Echocardiography</description>
          <population>Analysis includes participants who completed intervention and final study assessment</population>
          <units>percent ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Level as a Measure of Renal Function</title>
        <description>Serum creatinine</description>
        <time_frame>3 months</time_frame>
        <population>Analysis includes participants who completed intervention and final study assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Level as a Measure of Renal Function</title>
          <description>Serum creatinine</description>
          <population>Analysis includes participants who completed intervention and final study assessment</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tamara Horwich, MD, MS</name_or_title>
      <organization>University of California Los Angeles</organization>
      <phone>310-825-8816</phone>
      <email>thorwich@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

